Drug
Dpx Survivac
Dpx Survivac: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| DPX-Survivac NCT03836352 | Phase 2 | Ovarian Cancer |
Latest
No recent events.
Follow Dpx Survivac on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.